Pharmaceutical News

Ionis Pharmaceuticals 2024 Performance Report Financial statements Ionis Pharmaceuticals Ionis Pharmaceuticals reported a 2024 revenue decline of 11%, with a $475 million operating loss. The report highlights product sales from Spinraza, Wainua, Qalsody, and others, alongside its cash reserves and 2025 guidance.
Medpace's 2024 Financial Report Medpace Financial statements Medpace’s 2024 financial report shows impressive growth, with a 50% surge in Q4 net profit and a 43% annual increase. The company forecasts 2025 revenue between $2.11B and $2.21B, continuing strong performance in the global CRO industry.
2024 FDA Issued CRLs FDA Astellas Daiichi Sankyo AbbVie Novo Nordisk Johnson & Johnson The FDA issued Complete Response Letters (CRLs) for multiple drug applications in 2024, citing concerns about efficacy, safety, and manufacturing. Learn about the rejected drugs, reasons behind CRLs, and their impact on pharmaceutical companies.
JPM 2025: China's Biopharmaceutical Surprises, Bubbles, and Landing JPM The recent JPM conference in San Francisco witnessed significant discussions in the biotech sector, with Chinese biotech companies making notable strides despite a challenging market environment.
Trump's Presidency: Impact on the U.S. Biopharma Industry FDA NIH IRA Biosecure Act Explore the implications of Trump's return on U.S. biopharma: healthcare cost reforms, IRA adjustments, reshoring manufacturing, and FDA/NIH shifts. Key focus areas for Chinese pharma include supply chain resilience and navigating new cross-border data regulations.
What New Products and Models Are JPM Multinationals Focusing On in 2025? JPM Discover the latest trends in the 2025 biopharma industry! From Johnson & Johnson's $14.6B acquisition to Eli Lilly's impressive revenue growth, major M&As, and cutting-edge therapies across oncology, neuroscience, and ophthalmology reshaping global pharma.
Fat Loss Without Muscle Loss: A New Frontier in Weight Management Weight loss Ascletis Pharma Explore the latest advancements in weight loss drugs focusing on fat reduction and muscle preservation. Learn about promising treatments like ASC47, ActRIIA/B inhibitors, and their impact on obesity and muscle mass.
5 FDA Decisions to Watch in Q1 2025 FDA Discover the top 5 FDA decisions to watch in Q1 2025, including key drug approvals like Leqembi for Alzheimer's, Dato-DXd for breast cancer, and more groundbreaking treatments.
Betta Pharmaceuticals: ALK Inhibitor Ensartinib Approved by FDA FDA Betta Pharmaceuticals' Ensartinib (Ensacove), a next-generation ALK inhibitor, has been approved by the FDA for treating ALK-positive, advanced or metastatic NSCLC patients who haven't received prior ALK therapy, offering a new treatment option with promising results.
Teva Stock Soars 26%! Teva Pharmaceuticals Sanofi Teva Pharmaceuticals' stock surged 26% after the TL1A antibody duvakitug demonstrated strong efficacy in treating ulcerative colitis (UC) and Crohn's disease (CD). The Phase 2b RELIEVE study showed promising results, with duvakitug outperforming existing treatments.